JP2022549545A - 抗コリン薬の調製のための連続プロセス - Google Patents

抗コリン薬の調製のための連続プロセス Download PDF

Info

Publication number
JP2022549545A
JP2022549545A JP2021574905A JP2021574905A JP2022549545A JP 2022549545 A JP2022549545 A JP 2022549545A JP 2021574905 A JP2021574905 A JP 2021574905A JP 2021574905 A JP2021574905 A JP 2021574905A JP 2022549545 A JP2022549545 A JP 2022549545A
Authority
JP
Japan
Prior art keywords
anticholinergic
bromide
anticholinergic drug
preparing
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021574905A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549545A5 (https=
Inventor
カッツ，マリアンナ
ロレンソ，ヌーノ トレス
Original Assignee
ホビオネ サイエンティア リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71120199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2022549545(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ホビオネ サイエンティア リミテッド filed Critical ホビオネ サイエンティア リミテッド
Publication of JP2022549545A publication Critical patent/JP2022549545A/ja
Publication of JP2022549545A5 publication Critical patent/JP2022549545A5/ja
Priority to JP2025025794A priority Critical patent/JP2025081547A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021574905A 2019-06-17 2020-06-16 抗コリン薬の調製のための連続プロセス Pending JP2022549545A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025025794A JP2025081547A (ja) 2019-06-17 2025-02-20 抗コリン薬の調製のための連続方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT115583A PT115583B (pt) 2019-06-17 2019-06-17 Processo contínuo para a preparação de medicamentos anticolinérgicos
PT115583 2019-06-17
PCT/GB2020/051448 WO2020254791A1 (en) 2019-06-17 2020-06-16 Continuous process for the preparation of anticholinergic drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025025794A Division JP2025081547A (ja) 2019-06-17 2025-02-20 抗コリン薬の調製のための連続方法

Publications (2)

Publication Number Publication Date
JP2022549545A true JP2022549545A (ja) 2022-11-28
JP2022549545A5 JP2022549545A5 (https=) 2024-08-01

Family

ID=71120199

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021574905A Pending JP2022549545A (ja) 2019-06-17 2020-06-16 抗コリン薬の調製のための連続プロセス
JP2025025794A Pending JP2025081547A (ja) 2019-06-17 2025-02-20 抗コリン薬の調製のための連続方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025025794A Pending JP2025081547A (ja) 2019-06-17 2025-02-20 抗コリン薬の調製のための連続方法

Country Status (10)

Country Link
US (1) US20220251078A1 (https=)
EP (1) EP3982923B1 (https=)
JP (2) JP2022549545A (https=)
KR (1) KR20220024433A (https=)
CN (1) CN114206863A (https=)
AU (1) AU2020296972B2 (https=)
CA (1) CA3141271A1 (https=)
IL (1) IL288972A (https=)
PT (1) PT115583B (https=)
WO (1) WO2020254791A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013133335A (ja) * 2011-12-22 2013-07-08 Cerbios - Pharma Sa 環式第３級アミンをアルキル化するための連続方法
JP2015524832A (ja) * 2012-08-15 2015-08-27 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 化学的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
JP2008540367A (ja) * 2005-05-02 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規結晶性臭化チオトロピウム
WO2006117299A2 (en) 2005-05-02 2006-11-09 Boehringer Ingelheim International Gmbh Novel crystalline forms of tiotropium bromide
RU2453547C2 (ru) 2005-12-19 2012-06-20 Сикор Инк. Новые формы тиотропия бромида и способы их получения
US8163913B2 (en) 2005-12-19 2012-04-24 Sicor Inc. Forms of tiotropium bromide and processes for preparation thereof
JP5333342B2 (ja) 2009-06-29 2013-11-06 株式会社デンソー 半導体装置
PT106142B (pt) 2012-02-10 2014-07-18 Hovione Farmaci Ncia S A Processo para a preparação de brometo de tiotrópio
CZ27764U1 (cs) 2014-08-22 2015-02-02 Zentiva, K.S. uMethanolový solvát umeclidinium bromidu
PT108370B (pt) * 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
PT109740B (pt) 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013133335A (ja) * 2011-12-22 2013-07-08 Cerbios - Pharma Sa 環式第３級アミンをアルキル化するための連続方法
JP2015524832A (ja) * 2012-08-15 2015-08-27 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 化学的方法

Also Published As

Publication number Publication date
PT115583A (pt) 2021-06-03
IL288972A (en) 2022-02-01
EP3982923B1 (en) 2024-05-15
EP3982923A1 (en) 2022-04-20
JP2025081547A (ja) 2025-05-27
WO2020254791A1 (en) 2020-12-24
CA3141271A1 (en) 2020-12-24
EP3982923C0 (en) 2024-05-15
KR20220024433A (ko) 2022-03-03
PT115583B (pt) 2022-05-02
AU2020296972A1 (en) 2022-01-20
AU2020296972B2 (en) 2025-04-24
CN114206863A (zh) 2022-03-18
US20220251078A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
US11634377B2 (en) Fenfluramine compositions and methods of preparing the same
KR101290893B1 (ko) 피롤리디늄 염의 제조 방법
IE59056B1 (en) 4-benzyl-1-(2h)-phthalazinone derivatives
RS50904B (sr) Derivati tropana i njihova primena
IE55110B1 (en) Quaternary 6,11-dihydro-dibenzo(b,e)thiepin-11-n-alkyl-norscopien ethers and processes for their preparation
JP2011530489A (ja) キヌクリジンカーボネート誘導体およびその医薬組成物
JP2022088623A (ja) 臭化ウメクリジニウムの調製プロセス
CN102947300B (zh) 生物碱氨基酯衍生物及其药物组合物
EP3982923B1 (en) Continuous process for the preparation of anticholinergic drugs
CN103965179A (zh) 作为m3毒蕈碱性受体拮抗剂的吡咯烷鎓衍生物的多晶型物、其制备方法及药物组合物
ES2986962T3 (es) Proceso continuo para la preparación de fármacos anticolinérgicos
JP7705351B2 (ja) ＰＬＫ４阻害剤である（１Ｒ，２Ｓ）－（Ｅ）－２－（３－（４－（（ｃｉｓ－２，６－ジメチルモルホリノ）メチル）スチリル）－１Ｈ－イミダゾール－６－イル）－５’－メトキシスピロ［シクロプロパン－１，３’－インドリン］－２’－オンフマル酸塩のＳ４結晶形
CN111670191B (zh) 吡啶酮衍生物的晶型及制备方法和应用
EP3468949B1 (en) Crystalline pharmaceutical co-crystals of glycopyrronium bromide with lactose
WO1993023036A1 (fr) Compose de pyrazole condense optiquement actif, pour le traitement de la thrombocytopenie et de l&#39;erythropenie
CN111574529A (zh) 蕈毒碱受体M3拮抗剂和β2-肾上腺素能受体激动剂桥环衍生物
JP2012519680A (ja) ジヒドロベンゾオキサゾール−６−イル−アセトアミド誘導体の新規結晶性水和物、非晶質体、多形体およびその調製プロセス
JPH06510064A (ja) 置換イミダゾベンズオキサジン−１−オンの誘導体及び該誘導体の製造方法
KR20130099132A (ko) 4-[2-디메틸아미노-1-(1-하이드록시사이클로헥실)에틸]페닐 4-메틸벤조에이트 하이드로클로라이드의 다형체, 이의 제조 방법 및 이의 용도
JP2022549545A5 (https=)
HK1181769A (en) Process for the preparation of glycopyrronium chloride

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20220215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230320

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20231117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240723

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250220